Vanda Pharmaceuticals Inc.
VNDANasdaq
$5.44
↓ -0.2%Jul 17 close · end-of-day
Price
1Y↑ +13.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$323.5M
Enterprise Value
$269.4M
P/E
—
P/S
1.5
P/B
1.2
EV/EBITDA
—
PEG
—
FCF Yield
-39.4%
Dividend Yield
—
Revenue (TTM)
$217.8M
Net Income (TTM)
-$239.6M
Free Cash Flow (TTM)
-$127.3M
Gross Margin
—
Operating Margin
-73.6%
Net Margin
-110.0%
ROE
-85.3%
ROIC
-55.9%
Debt / Equity
—
Net Cash
$54.0M
Return 1Y
+11.9%
Company profile
Vanda Pharmaceuticals Inc. focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders. Its products under development include Fanapt (iloperidone) and Tradipitant (VLY-686) The company markets its products in the United States, Europe, and Israel.
- CEO
- Mihael H. Polymeropoulos
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 290
- Headquarters
- District Of Columbia
- Website
- vandapharma.com
Management & directors
- Mcguire Daniel PatrickSVP, GC and Secretary
- Birznieks GuntherSVP, Business Development
- Moran Kevin PatrickSVP, CFO & Treasurer
- Polymeropoulos Mihael HristosPresident and CEO
- Wijkstrom JoakimSVP, Chief Marketing Officer
- Williams TimothySVP & General Counsel
Roles derived from SEC Form 4 filings.
Earnings
VNDA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$51.7M↑ +3.4%
Diluted EPS-$0.82↑ +64.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $248.2M | $268.7M | $254.4M | $192.6M | $198.8M | $216.1M |
| Gross profit | — | — | — | — | — | — |
| Operating income | $27.2M | $42.2M | $6.3M | -$14.0M | -$40.7M | -$151.2M |
| Net income | $23.3M | $33.2M | $6.3M | $2.5M | -$18.9M | -$220.5M |
| Diluted EPS | $0.42 | $0.58 | $0.11 | $0.04 | -$0.33 | -$3.74 |
| Operating cash flow | $51.8M | $64.2M | $32.0M | $12.8M | -$15.8M | -$109.4M |
| Free cash flow | $50.0M | $63.7M | $31.3M | $12.4M | -$16.2M | -$110.4M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 11.0% | 15.7% | 2.5% | -7.2% | -20.5% | -70.0% |
| Net margin | 9.4% | 12.4% | 2.5% | 1.3% | -9.5% | -102.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $50.5M | $47.7M | $53.2M | $50.0M | $52.6M | $56.3M | $57.2M | $51.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$10.1M | -$11.0M | -$10.3M | -$41.0M | -$38.5M | -$31.3M | -$40.4M | -$50.2M |
| Net income | -$4.5M | -$5.3M | -$4.9M | -$29.5M | -$27.2M | -$22.6M | -$141.2M | -$48.6M |
| Diluted EPS | -$0.08 | -$0.09 | -$0.09 | -$0.50 | -$0.46 | -$0.38 | -$2.40 | -$0.82 |
| Operating cash flow | -$6.9M | -$14.6M | -$1.8M | -$33.1M | -$15.3M | -$31.6M | -$29.4M | -$50.2M |
| Free cash flow | -$7.0M | -$14.7M | -$2.0M | -$33.6M | -$15.6M | -$31.8M | -$29.5M | -$50.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -20.1% | -23.1% | -19.3% | -82.0% | -73.2% | -55.6% | -70.5% | -97.1% |
| Net margin | -9.0% | -11.2% | -9.2% | -58.9% | -51.7% | -40.1% | -246.8% | -93.9% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-04 | McGuire Daniel Patrick· SVP, GC and Secretary | Award | 80,000 | $0.00 | $0.00 | filing |
| 2026-06-04 | Chrousos Phaedra | Award | 41,600 | $0.00 | $0.00 | filing |
| 2026-06-04 | Duncan Charles Cliff | Award | 41,600 | $0.00 | $0.00 | filing |
| 2026-06-04 | DUGAN RICHARD W | Award | 41,600 | $0.00 | $0.00 | filing |
| 2026-06-04 | Ward Anne Sempowski | Award | 41,600 | $0.00 | $0.00 | filing |
| 2026-06-04 | Honore Tage | Award | 41,600 | $0.00 | $0.00 | filing |
| 2026-06-04 | Mitchell Stephen Ray | Award | 41,600 | $0.00 | $0.00 | filing |
| 2026-05-18 | Mitchell Stephen Ray | Gift | 25,836 | $0.00 | $0.00 | filing |
| 2026-04-22 | Duncan Charles Cliff | Award | 57,101 | $0.00 | $0.00 | filing |
| 2026-03-02 | Polymeropoulos Mihael Hristos· President and CEO | Sale | 156,235 | $8.17 | $1.3M | filing |
| 2026-03-02 | Moran Kevin Patrick· SVP, CFO & Treasurer | Sale | 42,442 | $8.27 | $350,821.33 | filing |
| 2026-03-02 | Williams Timothy· SVP & General Counsel | Sale | 42,434 | $8.27 | $350,755.20 | filing |
| 2026-03-02 | Birznieks Gunther· SVP, Business Development | Sale | 42,431 | $8.27 | $350,730.40 | filing |
| 2026-03-02 | Wijkstrom Joakim· SVP, Chief Marketing Officer | Sale | 30,800 | $8.27 | $254,589.72 | filing |
| 2026-02-23 | Honore Tage | Sale | 30,000 | $8.03 | $240,900.00 | filing |
| 2026-02-18 | Polymeropoulos Mihael Hristos· President and CEO | Award | 525,000 | $0.00 | $0.00 | filing |
| 2026-02-18 | Birznieks Gunther· SVP, Business Development | Award | 125,000 | $0.00 | $0.00 | filing |
| 2026-02-18 | Wijkstrom Joakim· SVP, Chief Marketing Officer | Award | 125,000 | $0.00 | $0.00 | filing |
| 2026-02-18 | Williams Timothy· SVP & General Counsel | Award | 125,000 | $0.00 | $0.00 | filing |
| 2026-02-18 | Moran Kevin Patrick· SVP, CFO & Treasurer | Award | 125,000 | $0.00 | $0.00 | filing |
| 2025-08-07 | Polymeropoulos Mihael Hristos· President and CEO | Buy | 10,000 | $4.15 | $41,500.00 | filing |
Latest 21 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.